HPV18 ‐Positive Cervical Large Cell Neuroendocrine Carcinoma With Rapid Progression Despite Pembrolizumab Combined With Chemotherapy: A Case Report With Immunogenomic Insights
- 28 July 2026
- journal article
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 52 (8)
Abstract
HPV18‐positive cervical large cell neuroendocrine carcinoma (LCNEC) is exceptionally rare. We report a 40‐years‐old woman with FIGO 2018 stage IVB LCNEC who progressed rapidly despite paclitaxel–carboplatin–bevacizumab plus pembrolizumab, followed by concurrent chemoradiotherapy and later cytotoxic regimens. Biopsy showed chromogranin A and synaptophysin positivity, diffuse p16, and Ki‐67%~80%. Comprehensive profiling revealed very low tumor mutational burden (TMB, 1.21/Mb), microsatellite stability, no homologous recombination deficiency, and minimal PD‐L1 (~1%), consistent with a poorly immunogenic tumor microenvironment (TME). This profile may explain the limited effect of immune checkpoint inhibition in this histology. The case suggests that HPV or p16 positivity alone did not predict clinical benefit from pembrolizumab‐based therapy in advanced cervical LCNEC, and supports careful biological assessment before treatment selection. These observations provide practical guidance for clinicians and support evaluation of alternative or investigational strategies for this aggressive tumor.Keywords
This publication has 15 references indexed in Scilit:
- Relative survival of large cell to small cell neuroendocrine carcinoma of the uterine cervixInternational Journal of Gynecological Cancer, 2025
- Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancersJournal for ImmunoTherapy of Cancer, 2025
- Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyAnnals of Oncology, 2024
- Incorporation of immunotherapy into the treatment of metastatic neuroendocrine carcinoma of the cervix: A case reportGynecologic Oncology Reports, 2023
- Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the CervixApplied Immunohistochemistry & Molecular Morphology, 2020
- Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tractGynecologic Oncology, 2020
- The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasmsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)Lung Cancer, 2019
- Large cell neuroendocrine carcinoma of the cervix: Prognostic factors and survival advantage with platinum chemotherapyGynecologic Oncology, 2011
- Human Papillomavirus Type and Clinical Manifestation in Seven Cases of Large-cell Neuroendocrine Cervical CarcinomaJournal of the Formosan Medical Association, 2009